SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) November 13, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On November 13, 1997, Biocontrol Technology, Inc. (NASDAQ:BICO) announced
today that although there can be no guarantees, it plans to submit by
year end to the Food and Drug Administration (FDA) for marketing
approval on the Diasensor 1000 noninvasive glucose sensor for
diabetics. The Company also stated that its schedule to obtain a CE
mark in the first quarter of 1998 for marketing the Diasensor in Europe
continues on target. The Company further announced that shipment of
Diasensor 1000s to Manila, Philippines is scheduled in the third or
fourth week of November.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper, CEO
DATED: November 13, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL PLANS FDA SUBMISSION ON DIASENSOR 1000 BY THE END OF 1997
Pittsburgh, PA - November 13, 1997 - Biocontrol Technology, Inc. (Nasdaq:BICO)
announced today that although there can be no guarantees, it plans to
submit by year end to the Food and Drug Administration (FDA) for
marketing approval on the Diasensor 1000 noninvasive glucose sensor for
diabetics. Based on a recent meeting with the FDA, additional in-home
patients will be added and included in this submission because of the
improved results from calibrating the Diasensor to patients in their
homes rather than in a clinical setting. The Company also stated today
that its schedule to obtain a CE mark in the first quarter of 1998 for
marketing the Diasensor in Europe continues on target. The Company
further announced that shipment of Diasensor 1000s to Manila,
Philippines is scheduled in the third or fourth week of November. Using
near-infrared technology, the Diasensor 1000 measures glucose in the
blood without the need to finger prick. Biocontrol Technology, Inc.
(www.bico.com) has its corporate offices in Pittsburgh, PA and is
involved in the development and manufacture of biomedical devices and
environmental products.
